Biotech entity
clinical-trial is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Bispecific Antibody, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 2.8 for the same window.
Last mentioned: Mar 20, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
clinical-trial is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Bispecific Antibody, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 2.8 for the same window. The 6 average consequence score is below the beat benchmark of 6.4 in the same window. PH-HFpEF appears in 1 tracked Biotech story from March 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering PH-HFpEF. Shared-story counts are live from our verified record — not editorial picks.
IND Filing
Potential window for Investigational New Drug application with the FDA.
Preclinical Initiation
Start of IND-enabling studies and toxicology assessments.
Candidate Selection
Expected naming of the lead development candidate for the program.
Strategy Announcement
iBio outlines bispecific approach for PH-HFpEF.
iBio is advancing its bispecific antibody strategy to address Pulmonary Hypertension associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), a major unmet medical need. The company expects to select a formal development candidate by the third quarter of 2026, signaling a transition from discovery to preclinical development for its lead cardiovascular program.
Source: finance.yahoo.com · themarketsdaily.com
PH-HFpEF is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
